Eris Lifesciences IPO
Eris Lifesciences IPO — date, price band, lot size & details 2017
Eris Lifesciences listed on 29 Jun 2017 at ₹611, 1.3% above the ₹603 issue price.
Eris Lifesciences is an Ahmedabad based pharmaceutical company focused on chronic and acute therapies prescribed by specialists, such as diabetes. Its total income was Rs 707.44 crore in FY2017.
Stock price
Eris Lifesciences is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 14 November.
- Open 16 Jun 2017
- Close 20 Jun 2017
- Allotment 23 Jun 2017
- Refund/credit 27 Jun 2017
- Listing 29 Jun 2017
Issue summary
The terms of the offer, as filed.
| IPO Dates | 16 to 20 Jun, 2017 |
|---|---|
| Price Band | ₹600 – ₹603 |
| Face Value | ₹1 |
| Lot Size | 24 Shares |
| Issue Size | ₹1740.49 Cr |
| Sale Type | OFS only |
| Listing On | BSE, NSE |
| Employee Discount | Rs 60.00 per share |
| Registrar | MUFG Intime India Private Limited |
| Min Investment | ₹ 14,472 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 24 shares at the ₹603 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 24 | ₹14,472 |
| Retail (max) | 13 | 312 | ₹1,88,136 |
| S-HNI (min) | 14 | 336 | ₹2,02,608 |
| S-HNI (max) | 69 | 1,656 | ₹9,98,568 |
| B-HNI (min) | 70 | 1,680 | ₹10,13,040 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 4
- 01Total income rose from Rs 551.41 crore in FY2015 to Rs 707.44 crore in FY2017.
- 02Profit after tax rose from Rs 83.33 crore in FY2015 to Rs 242.57 crore in FY2017.
- 03It had no borrowing in FY2016 and FY2017.
- 04Net worth rose from Rs 267.37 crore in FY2015 to Rs 547.92 crore in FY2017.
Risks · 5
- 01It depends on the Indian market, so drug price controls can hit its products; total assets were Rs 630.00 crore.
- 02Chronic therapies such as diabetes face strong competition from many brands; profit was Rs 137.97 crore in FY2016.
- 03The whole Rs 1,740.49 crore issue was an offer for sale, so none of it went to the company.
- 04Its high margins may draw rivals; profit was Rs 242.57 crore on income of Rs 707.44 crore in FY2017.
- 05Promoters held 59.18% before the issue and 55.93% after it.
Three years of numbers
All figures in ₹ crore, as reported in the Eris Lifesciences offer document.
| Metric | 31 Mar 2017 | 31 Mar 2016 | 31 Mar 2015 |
|---|---|---|---|
| Assets | 630.00 | 402.12 | 353.88 |
| Total Income | 707.44 | 608.77 | 551.41 |
| Profit After Tax | 242.57 | 137.97 | 83.33 |
| NET Worth | 547.92 | 305.35 | 267.37 |
| Reserves and Surplus | 534.17 | 305.21 | 267.24 |
| Total Borrowing | 0.50 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Where the money goes
How the company intends to use the proceeds of the issue.
Information about the usage of proceeds from the Eris Lifesciences IPO will be updated shortly.
Eris Lifesciences IPO Anchor Investors
37 anchor investors across 16 fund houses committed ₹779.47 Cr a day before the issue opened.
Anchor investors bid a day before the issue opens and are locked in after allotment, so a book weighted towards domestic mutual funds is generally read as a stronger signal than one filled by short-horizon funds. Browse every anchor investor scheme or fund house we track.
About the company
It researches, develops, makes and sells products in selected chronic and acute therapy areas of the Indian pharma market.
Its portfolio focuses on therapies that need specialist and super specialist doctors, such as diabetologists.
The IPO was Rs 1,740.49 crore and was entirely an offer for sale at Rs 603, the top of the Rs 600 to Rs 603 band, so the company received no money.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Eris Lifesciences IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Axis Capital
255 issues handledBest listing: Latent View Analytics (+160.0%). Weakest: Shriram Properties (-23.7%).
Citigroup Global Markets India Pvt. Ltd
74 issues handledBest listing: Tata Technologies (+140.0%). Weakest: Puravankara Projects (-22.5%).
Credit Suisse Securities (India) Pvt. Ltd
20 issues handledBest listing: Zomato (+52.6%). Weakest: Sterling & Wilson Solar (-9.5%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Eris Lifesciences?
The current Grey Market Premium is ₹9, or 1% over the issue price.
What is the Eris Lifesciences IPO price band?
₹600 to ₹603, on a face value of ₹1.
When is the allotment?
The basis of allotment is 23 June 2017, with listing on 29 June 2017.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — MUFG Intime India Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
